Axsome Other Assets vs Long Term Debt Total Analysis

AXSM Stock

USD 71.71 0.19 0.27%

Axsome Therapeutics financial indicator trend analysis is way more than just evaluating Axsome Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Axsome Therapeutics is a good investment. Please check the relationship between Axsome Therapeutics Other Assets and its Long Term Debt Total accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Axsome Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.

To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.

Other Assets vs Long Term Debt Total

Other Assets vs Long Term Debt Total Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Axsome Therapeutics Other Assets account and Long Term Debt Total. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Axsome Therapeutics' Other Assets and Long Term Debt Total is -0.29. Overlapping area represents the amount of variation of Other Assets that can explain the historical movement of Long Term Debt Total in the same time period over historical financial statements of Axsome Therapeutics, assuming nothing else is changed. The correlation between historical values of Axsome Therapeutics' Other Assets and Long Term Debt Total is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Assets of Axsome Therapeutics are associated (or correlated) with its Long Term Debt Total. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Long Term Debt Total has no effect on the direction of Other Assets i.e., Axsome Therapeutics' Other Assets and Long Term Debt Total go up and down completely randomly.

Correlation Coefficient

-0.29

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Other Assets

Long Term Debt Total

Most indicators from Axsome Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Axsome Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Axsome Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.

To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.At this time, Axsome Therapeutics' Selling General Administrative is very stable compared to the past year. As of the 27th of April 2024, Tax Provision is likely to grow to about 1 M, while Sales General And Administrative To Revenue is likely to drop 0.78.

Axsome Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Other Liab	Net Tangible Assets	Current Deferred Revenue	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Non Current Liabilities Total
Total Assets		0.83	0.86	0.86	0.71	-0.8	-0.74	0.81	0.87	0.87	0.42	0.48	0.86	0.87	0.85	0.89	-0.19	0.51	0.43	0.41	0.59	0.84	0.79	0.55	0.82	0.84
Short Long Term Debt Total	0.83		0.98	0.98	0.5	-0.77	-0.97	0.95	0.93	0.93	0.59	0.68	0.94	0.96	1.0	0.96	-0.36	0.67	0.54	0.23	0.78	0.92	0.86	0.02	1.0	1.0
Other Current Liab	0.86	0.98		0.99	0.63	-0.72	-0.94	0.95	0.89	0.89	0.51	0.61	0.96	0.99	1.0	0.94	-0.32	0.61	0.48	0.15	0.7	0.96	0.92	0.12	0.98	0.99
Total Current Liabilities	0.86	0.98	0.99		0.57	-0.77	-0.96	0.98	0.92	0.92	0.58	0.68	0.94	0.99	0.99	0.96	-0.32	0.68	0.53	0.23	0.77	0.97	0.93	0.11	0.98	0.99
Total Stockholder Equity	0.71	0.5	0.63	0.57		-0.2	-0.34	0.45	0.36	0.36	-0.21	-0.12	0.66	0.69	0.56	0.44	0.03	-0.08	-0.1	-0.24	-0.05	0.67	0.64	0.66	0.5	0.56
Net Debt	-0.8	-0.77	-0.72	-0.77	-0.2		0.78	-0.8	-0.95	-0.95	-0.75	-0.76	-0.69	-0.69	-0.76	-0.91	0.33	-0.78	-0.67	-0.79	-0.89	-0.66	-0.62	-0.13	-0.77	-0.75
Retained Earnings	-0.74	-0.97	-0.94	-0.96	-0.34	0.78		-0.98	-0.92	-0.92	-0.73	-0.82	-0.86	-0.92	-0.96	-0.94	0.41	-0.8	-0.62	-0.29	-0.88	-0.91	-0.88	0.12	-0.97	-0.95
Accounts Payable	0.81	0.95	0.95	0.98	0.45	-0.8	-0.98		0.92	0.92	0.69	0.78	0.86	0.95	0.96	0.94	-0.42	0.77	0.6	0.32	0.85	0.96	0.94	0.02	0.96	0.94
Cash	0.87	0.93	0.89	0.92	0.36	-0.95	-0.92	0.92		1.0	0.7	0.76	0.86	0.87	0.93	0.99	-0.36	0.77	0.64	0.56	0.89	0.83	0.78	0.09	0.93	0.92
Cash And Short Term Investments	0.87	0.93	0.89	0.92	0.36	-0.95	-0.92	0.92	1.0		0.7	0.76	0.86	0.87	0.93	0.99	-0.36	0.77	0.64	0.56	0.89	0.83	0.78	0.09	0.93	0.92
Common Stock Total Equity	0.42	0.59	0.51	0.58	-0.21	-0.75	-0.73	0.69	0.7	0.7		0.96	0.45	0.47	0.56	0.65	-0.45	0.99	0.86	0.61	0.9	0.49	0.5	-0.27	0.58	0.53
Common Stock Shares Outstanding	0.48	0.68	0.61	0.68	-0.12	-0.76	-0.82	0.78	0.76	0.76	0.96		0.52	0.58	0.66	0.72	-0.38	0.97	0.74	0.54	0.93	0.61	0.61	-0.26	0.68	0.64
Other Current Assets	0.86	0.94	0.96	0.94	0.66	-0.69	-0.86	0.86	0.86	0.86	0.45	0.52		0.95	0.95	0.91	-0.28	0.55	0.53	0.13	0.61	0.88	0.81	0.2	0.94	0.96
Other Stockholder Equity	0.87	0.96	0.99	0.99	0.69	-0.69	-0.92	0.95	0.87	0.87	0.47	0.58	0.95		0.98	0.91	-0.3	0.58	0.44	0.12	0.66	0.98	0.94	0.18	0.96	0.98
Total Liab	0.85	1.0	1.0	0.99	0.56	-0.76	-0.96	0.96	0.93	0.93	0.56	0.66	0.95	0.98		0.96	-0.33	0.66	0.52	0.21	0.76	0.95	0.9	0.08	1.0	1.0
Total Current Assets	0.89	0.96	0.94	0.96	0.44	-0.91	-0.94	0.94	0.99	0.99	0.65	0.72	0.91	0.91	0.96		-0.34	0.73	0.61	0.47	0.85	0.87	0.81	0.11	0.96	0.96
Short Term Debt	-0.19	-0.36	-0.32	-0.32	0.03	0.33	0.41	-0.42	-0.36	-0.36	-0.45	-0.38	-0.28	-0.3	-0.33	-0.34		-0.46	-0.51	-0.22	-0.45	-0.34	-0.35	0.23	-0.36	-0.33
Common Stock	0.51	0.67	0.61	0.68	-0.08	-0.78	-0.8	0.77	0.77	0.77	0.99	0.97	0.55	0.58	0.66	0.73	-0.46		0.85	0.57	0.92	0.6	0.61	-0.21	0.67	0.63
Other Liab	0.43	0.54	0.48	0.53	-0.1	-0.67	-0.62	0.6	0.64	0.64	0.86	0.74	0.53	0.44	0.52	0.61	-0.51	0.85		0.53	0.76	0.44	0.43	-0.14	0.53	0.5
Net Tangible Assets	0.41	0.23	0.15	0.23	-0.24	-0.79	-0.29	0.32	0.56	0.56	0.61	0.54	0.13	0.12	0.21	0.47	-0.22	0.57	0.53		0.65	0.12	0.12	0.11	0.23	0.2
Current Deferred Revenue	0.59	0.78	0.7	0.77	-0.05	-0.89	-0.88	0.85	0.89	0.89	0.9	0.93	0.61	0.66	0.76	0.85	-0.45	0.92	0.76	0.65		0.67	0.65	-0.25	0.78	0.74
Non Current Assets Total	0.84	0.92	0.96	0.97	0.67	-0.66	-0.91	0.96	0.83	0.83	0.49	0.61	0.88	0.98	0.95	0.87	-0.34	0.6	0.44	0.12	0.67		0.99	0.18	0.93	0.93
Non Currrent Assets Other	0.79	0.86	0.92	0.93	0.64	-0.62	-0.88	0.94	0.78	0.78	0.5	0.61	0.81	0.94	0.9	0.81	-0.35	0.61	0.43	0.12	0.65	0.99		0.17	0.87	0.87
Other Assets	0.55	0.02	0.12	0.11	0.66	-0.13	0.12	0.02	0.09	0.09	-0.27	-0.26	0.2	0.18	0.08	0.11	0.23	-0.21	-0.14	0.11	-0.25	0.18	0.17		0.01	0.06
Long Term Debt	0.82	1.0	0.98	0.98	0.5	-0.77	-0.97	0.96	0.93	0.93	0.58	0.68	0.94	0.96	1.0	0.96	-0.36	0.67	0.53	0.23	0.78	0.93	0.87	0.01		1.0
Non Current Liabilities Total	0.84	1.0	0.99	0.99	0.56	-0.75	-0.95	0.94	0.92	0.92	0.53	0.64	0.96	0.98	1.0	0.96	-0.33	0.63	0.5	0.2	0.74	0.93	0.87	0.06	1.0

Click cells to compare fundamentals

Axsome Therapeutics Account Relationship Matchups

Axsome Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	220.5M	186.1M	(338.4M)	331.5M	588.2M	617.6M
Short Long Term Debt Total	19.9M	50.1M	49.7M	94.7M	186.4M	195.7M
Other Current Liab	683.2K	8.7M	9.3M	57.5M	96.9M	101.8M
Total Current Liabilities	24.5M	23.4M	23.1M	96.6M	138.9M	145.8M
Total Stockholder Equity	(175.9M)	(278.8M)	(409.2M)	109.6M	191.0M	200.5M
Net Debt	(200.0M)	(133.8M)	(36.8M)	(106.2M)	(199.8M)	(189.8M)
Retained Earnings	(175.9M)	(278.8M)	(409.2M)	(596.3M)	(835.6M)	(793.8M)
Accounts Payable	10.9M	13.5M	13.1M	38.6M	40.7M	42.7M
Cash	220.0M	183.9M	86.5M	200.8M	386.2M	405.5M
Cash And Short Term Investments	220.0M	183.9M	86.5M	200.8M	386.2M	405.5M
Common Stock Total Equity	3.0K	3.7K	3.7K	3.8K	4.3K	2.7K
Common Stock Shares Outstanding	34.0M	37.2M	37.6M	40.7M	45.4M	30.1M
Liabilities And Stockholders Equity	(134.1M)	(206.5M)	(338.4M)	331.5M	588.2M	617.6M
Other Current Assets	413.1K	148.4K	45.3K	2.8M	8.1M	8.5M
Other Stockholder Equity	(3.7K)	(3.7K)	(3.8K)	705.9M	1.0B	1.1B
Total Liab	41.8M	72.3M	70.8M	221.9M	397.3M	417.1M
Total Current Assets	220.4M	184.0M	86.5M	245.6M	504.3M	529.5M
Short Term Debt	2.6M	1.2M	620.7K	424.7K	1.3M	1.3M
Common Stock	3.7K	3.7K	3.8K	4.4K	5K	3.2K
Net Tangible Assets	178.7M	113.8M	15.6M	39.6M	45.5M	52.6M
Non Current Assets Total	170.5K	2.1M	1.3M	85.8M	84.0M	88.2M
Non Currrent Assets Other	139.9K	317.4K	322.9K	14.7M	11.0M	11.6M
Other Assets	139.9K	2.1M	(426.1M)	14.7M	13.2M	13.9M
Long Term Debt	17.3M	48.3M	49.1M	94.3M	178.1M	187.0M
Non Current Liabilities Total	17.3M	48.9M	49.1M	125.4M	258.4M	271.3M
Property Plant And Equipment Net	30.6K	1.8M	944.0K	1.1M	7.6M	8.0M
Property Plant And Equipment Gross	30.6K	1.8M	944.0K	1.1M	7.6M	8.0M
Property Plant Equipment	30.6K	52.6K	283.8K	1.1M	1.3M	1.4M
Retained Earnings Total Equity	(107.6M)	(175.9M)	(278.8M)	(409.2M)	(368.3M)	(349.9M)
Long Term Debt Total	3.6M	17.3M	48.3M	49.1M	56.5M	59.3M
Capital Surpluse	108.5M	354.6M	392.6M	424.8M	488.5M	264.6M
Net Invested Capital	198.7M	162.1M	64.7M	203.8M	369.0M	387.5M
Net Working Capital	195.9M	160.6M	63.5M	149.1M	365.4M	383.7M
Capital Stock	3.7K	3.7K	3.8K	4.4K	5K	4.3K

Axsome Therapeutics Investors Sentiment

The influence of Axsome Therapeutics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Axsome. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.

Investor biases related to Axsome Therapeutics' public news can be used to forecast risks associated with an investment in Axsome. The trend in average sentiment can be used to explain how an investor holding Axsome can time the market purely based on public headlines and social activities around Axsome Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.

Axsome Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Axsome Therapeutics' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Axsome Therapeutics' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Axsome Therapeutics.

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Axsome Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Axsome Therapeutics' short interest history, or implied volatility extrapolated from Axsome Therapeutics options trading.

Pair Trading with Axsome Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Axsome Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Axsome Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Axsome Stock

0.86	RZLT	Rezolute Financial Report 9th of May 2024	Pair Corr
0.79	HCWB	HCW Biologics	Pair Corr
0.77	RVMD	Revolution Medicines Financial Report 13th of May 2024	Pair Corr
0.73	ELEV	Elevation Oncology Earnings Call This Week	Pair Corr
0.62	A	Agilent Technologies Financial Report 28th of May 2024	Pair Corr

The ability to find closely correlated positions to Axsome Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Axsome Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Axsome Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Axsome Therapeutics to buy it.

The correlation of Axsome Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Axsome Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Axsome Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Axsome Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Axsome Therapeutics is a strong investment it is important to analyze Axsome Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Axsome Therapeutics' future performance. For an informed investment choice regarding Axsome Stock, refer to the following important reports:

How To Invest In Axsome

Details

Is Axsome Stock a good investment?

Details

What is Axsome Therapeutics' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Axsome Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.

To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.

You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.

Complementary Tools for Axsome Stock analysis

When running Axsome Therapeutics' price analysis, check to measure Axsome Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Axsome Therapeutics is operating at the current time. Most of Axsome Therapeutics' value examination focuses on studying past and present price action to predict the probability of Axsome Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Axsome Therapeutics' price. Additionally, you may evaluate how the addition of Axsome Therapeutics to your portfolios can decrease your overall portfolio volatility.

	Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios
	Risk-Return Analysis View associations between returns expected from investment and the risk you assume
	Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
	Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
	Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules
	Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated
	Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios
	Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market.
	Portfolio Anywhere Track or share privately all of your investments from the convenience of any device
	Economic Indicators Top statistical indicators that provide insights into how an economy is performing
	Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Global Correlations Find global opportunities by holding instruments from different markets

Is Axsome Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Axsome Therapeutics. If investors know Axsome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Axsome Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(5.27)

Revenue Per Share

5.957

Quarterly Revenue Growth

1.935

Return On Assets

(0.25)

Return On Equity

(1.59)

The market value of Axsome Therapeutics is measured differently than its book value, which is the value of Axsome that is recorded on the company's balance sheet. Investors also form their own opinion of Axsome Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Axsome Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Axsome Therapeutics' market value can be influenced by many factors that don't directly affect Axsome Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Axsome Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Axsome Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Axsome Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Axsome Other Assets vs Long Term Debt Total Analysis

Other Assets vs Long Term Debt Total

Other Assets vs Long Term Debt Total Correlation Analysis

Correlation Coefficient

Other Assets

Long Term Debt Total

Axsome Therapeutics fundamental ratios Correlations

Axsome Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Axsome Therapeutics fundamental ratios Accounts

Axsome Therapeutics Investors Sentiment

Pair Trading with Axsome Therapeutics

Moving against Axsome Stock

Complementary Tools for Axsome Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Liab	+ 1.0	Short Long Term Debt Total
Long Term Debt	+ 1.0	Short Long Term Debt Total
Non Current Liabilities Total	+ 1.0	Short Long Term Debt Total
Total Liab	+ 1.0	Other Current Liab
Cash And Short Term Investments	+ 1.0	Cash
Long Term Debt	+ 1.0	Total Liab

Accounts Payable	- 0.98	Retained Earnings
Long Term Debt	- 0.97	Retained Earnings
Retained Earnings	- 0.97	Short Long Term Debt Total
Total Liab	- 0.96	Retained Earnings
Retained Earnings	- 0.96	Total Current Liabilities
Non Current Liabilities Total	- 0.95	Retained Earnings